CKD 581

Drug Profile

CKD 581

Alternative Names: CKD-581

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chong Kun Dang
  • Class Antineoplastics
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Multiple myeloma
  • No development reported Lymphoma

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Lymphoma(Second-line therapy or greater) in South Korea (Parenteral, Injection)
  • 28 Apr 2018 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in South Korea (Parenteral, Injection)
  • 10 May 2017 Chong Kun Dang Pharmaceutical initiates enrolment in a phase I trial for Multiple myeloma (Second-line therapy or greater, Combination therapy) in South Korea (NCT03150316)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top